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Introduction
In recent years, probiotic supplements and probiotic yogurt 
have become increasingly popular pharmacy and grocery items. 
Proponents posit that these live cultures of beneficial bacteria 
counteract the negative effects of antibiotics and decreased mi-
crobial exposure of modern life, while others are skeptical of 
these relatively new products and claims. 
Every human gut contains millions of bacteria from hundreds of 
species which aid in digestion and promote health. These bac-
teria are healthy bacteria and are very important to one’s well-
being. Western, developed countries successfully controlled in-
fectious diseases during the last century by improving sanitation 
and using antibiotics and vaccines. At the same time, a rise in dis-
eases such as allergies, autoimmune disorders, and inflammato-
ry bowel disease has been observed in both adults and children, 
and it is hypothesized that improvements in hygiene, decreased 
microbial exposure in childhood, and decreased maintenance of 
microflora are responsible for this increase. In 1907, the Russian 
zoologist Élie Metchnikoff was the first one to suggest that gut 
microbes may influence human health (Britannica). 
Recent studies show that ingesting oral probiotics can promote 
health and counteract some negative effects of antibiotics, but 
only in specific ways. It is necessary to understand the mecha-
nisms and limitations of probiotic supplements in order to be 
an informed consumer.
Methods
This subject was researched using Touro College’s online library 
database as well as Google Scholar. Additionally, ProQuest, 
EBSCO, MEDLINE, and PubMed were used to search for arti-
cles. The author had free access to these search engines through 
the Touro College Library. The method of research entailed 
reviewing published articles and studies that have been peer 
reviewed. Key words such as “gut bacteria”, “probiotic bacteria”, 
“health promoting bacteria”, “probiotic yogurt”, “human micro-
biome”, and “microbiota” were used to find appropriate articles.
Background: Development of gut microbiome
Babies born via vaginal births are colonized by bacteria as they 
pass through the birth canal. The vaginal microbial communities 
appear to change during pregnancy to provide newborns with 
beneficial microbes; at the time of delivery, the vagina is domi-
nated by Lactobacillus and Prevotella spp (Krajmalnik-Brown et 
al 2012). Breast milk also populates the baby’s gut with additional 
health promoting bacteria from the Bifidobacterium family. 
According to very recent research, babies acquire stomach bac-
teria from their mothers even before birth. In healthy human fe-
tuses, bacteria have been detected in umbilical cord blood, fetal 
membranes, and amniotic fluid, supporting the notion of bac-
terial transmission through the placental barrier. Furthermore, 
the meconium (ingested amniotic fluid) from newborns has 
been shown to be non-sterile, home to a complex community 
of microbes, including Enterococci and Escherichia, commonly 
found in the adult GI tract. Therefore, even babies born by cae-
sarean section are born with microbiomes, despite lacking the 
vaginal exposure (Funkhouser and Bordenstein 2013). 
Diversity between ethnic groups
While 90% of all people’s gut biome is similar, the bacteria spe-
cies and proportions vary between races and ethnic groups. A 
study published in 2010 comparing rural children of Burkina 
Faso, Africa, with children in the modern and developed city 
of Florence, Italy, showed that Bacteroidetes and Spirochaetes 
were abundant in the microbiota of the African children and that 
the specific types that were increased were well suited to ex-
tract nutrition from their herbal-rich diet. These bacteria were 
from the genus Prevotella and Xylanibacter (Bacteroidetes) and 
Treponema (Spirochaetes), which are known for their skill at 
cellulose and xylan hydrolysis. The diet of the rural village in 
Burkina Faso is low in animal protein and fat but rich in starch, 
fiber, and plant polysaccharides from local herbs and vegeta-
bles. These bacteria were completely lacking in the European 
children whose diet was high in fat, animal protein, sugars, and 
nutrient-rich but thoroughly cleansed foods (De Filippo et al 
2010). 
A recent study has shown that the Japanese possess unique 
bacteria in their intestines which allow them to digest red 
algae, commonly used to wrap fish in sushi. Japanese have a sea-
weed-rich diet, eating on average of 14.2 grams of sushi a day. 
Red algae, used in sushi, contain the polysaccharide porphyran 
in their cell walls. It is broken down specifically by an enzyme 
called porphyranase. This enzymatic activity is unique to select 
marine bacteria such as Zobellia galactanivorans, the bacteria 
that populate the gut of the Japanese, giving them the machinery 
they need to digest these nutritional sea plants (Hehemann et 
al 2010).
A similar phenomena has been detected in the guts of rodents. 
Desert woodrats (Neotoma lepida) of the Mojave and Great 
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Basin deserts have special toxin-degrading gut microbes to di-
gest the toxic creosote and juniper bushes (Kohl et al 2014). 
This diversity between ethnic groups adds a dimension of com-
plexity to understanding the workings of the microbiome. This 
variation may impact the manner in which the gut responds to 
introduced probiotic bacteria and may result in probiotic treat-
ments being beneficial for some people but not others.
How gut microbes affect autrient absorption and 
energy regulation
In a way similar to how rhizoidal fungi allow plant roots to ab-
sorb soil nutrition, the biofilm structure of the many mucosal 
microbiota adhering to gut epithelium facilitates benefits for the 
host, including nutrient exchange and stimulation of immunity 
(Sonnenburg et al 2004). For example, Bacteroides thetaiotao-
micron is a major symbiont of the human adult gut (Hayashi 
et al 2013). This organism makes an important contribution 
to human digestion by breaking down complex plant material 
that innate human enzymes cannot digest. The human body can 
produce amylase and sucrase which break down starch, glyco-
gen, and sucrose respectively, yet it cannot independently digest 
complex plant material (Microbewiki). Using the plant and fungus 
polysaccharides ingested by the human host as its food source, 
B. thetaiotaomicron is able create small sugars with its glycoside 
hydrolases which  hydrolyze glycosidic bonds in complex sugars. 
It produces mucus that allows it to attach to the gut epithelial 
cells, avoiding washout from the microecosystem. The mucus 
sticks to epithelial lining as well as to undigested food particles. 
These aggregations serve to promote the assembly of more 
microbes and allow their syntrophic relationship with the gut.. 
Other gut bacterial species such as harmless strains of E. Coli 
benefit from the small sugars provided by B. thetaiotaomicron, 
which the E. Coli cannot produce independently. Methanogens, 
another family of the microbiome, use the short-chain fatty acid 
products of the fermentation of carbohydrates. These symbiotic 
relationships add productivity to the human gut (Sonnenburg 
et al 2004). It is clear that the many interactions between gut 
bacteria are extremely complex and to date only a fraction of 
this organization is understood. Much research is needed to 
fully understand the way in which introduced probiotic bacteria 
interrelate and network with the host gut microbiome.
Vitamins
Vitamin B12 is required for metabolism in cells and for the 
formation of red blood cells. The human body cannot produce 
vitamin B12. Only bacteria and archaea are capable of manu-
facturing this vitamin. Species of Pseudomonas and Klebsiella, 
normal residents of the human small intestine, have been shown 
to produce vitamin B12 (Albert et al 1980). E. coli in the large 
intestine produce Vitamin K2 (Bentley and Meganathan 1982). 
Biotin (vitamin B7), a vitamin required for production of fatty 
acids and cell growth, is synthesized in significant quantities by 
the intestinal flora (Scheinfeld et al 2015)..
Gut bacteria help prevent pathogenic infections
Lactic acid bacteria are found naturally in acidic foods such as 
pickles, olives, and yogurt, preventing spoilage by maintaining a 
low pH. In the same way, many pathogenic bacteria are deterred 
from growing in the human intestines due to the unfriendly 
acidic environment created by members of lactic acid bacteria 
family, Lactobacillales. Furthermore, by merely colonizing the 
gut, the healthy bacteria leave little real estate for pathogenic 
bacteria to occupy (Nester).
Having established the presence and functions of gut microbes, 
a question of concern is how the common use of antibiotics 
affects this microbiome and the life functions dependent upon it.
What happens to the bacteria when antibiotics 
are taken?
Studies on isolated cultured colonies of gut bacteria in a labo-
ratory setting have shown how antibiotics impact them. In one 
study, 14 common gut bacterial species from the Clostridium, 
Bifidobacterium, and Bacteroides genera were treated in vitro 
with ampicillin and metronidazole, clinically prescribed anti-
biotics. Effects on bacterial physiology and metabolism were 
monitored over a 48 hour period. Bacteroides and some 
Clostridium species were substantially reduced by Ampicillin. 
On bifidobacterial species ampicillin only had a bacteriostatic 
effect. Metronidazole strongly affected bacteroides communi-
ties, reduced some clostridium species, but had no effect on 
bifidobacterial communities. This study showed that the antibi-
otics ampicillin and metronidazole have a real inhibitory effect 
on some intestinal bacteria species but not others (Newton F 
et al 2013). 
 Modeling tests have been conducted on mice as well to bet-
ter understand the relationship between antibiotics and intes-
tinal bacteria. Mice have similar gut bacterial composition to 
humans. Oral intake of antibiotics, streptomycin and vancomy-
cin, was used to agitate the intestinal microbiota of the mice. 
Thereafter, the mice were infected with Salmonella enterica se-
rovar Typhimurium to gauge the results of antibiotic treatment. 
Analysis showed that the number of intestinal bacteria was not 
altered significantly by the antibiotic regimen, but the microbio-
ta composition was affected. Both vancomycin and streptomycin 
treatments significantly decreased lactobacilli and enterococci/
group D streptococci populations and promoted the over-
growth of Enterobacteriaceae. These perturbations in the mi-
crobiota caused the mice to be more susceptible to Salmonella 
serovar Typhimurium intestinal colonization and infection than 
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before antibiotic treatment. This study demonstrates the impor-
tance of a healthy microbiota in limiting susceptibility to enteric 
pathogens. This study showed that the antibiotics vancomycin 
and streptomycin can have a detrimental effect on intestinal 
bacteria species, limiting host immunity (Sekirov et al 2008). 
A leading expert in this field, David Relman M.D., investigated 
the gut bacterial communities of three healthy humans before 
and after treatment with ciprofloxacin, a commonly prescribed 
broad spectrum antibiotic of the fluoroquinolone family, by 
comparing stool samples before and after treatment. He mon-
itored them for a period of ten months. Ciprofloxacin treat-
ment eliminated about a third of the bacterial taxa in the gut, 
decreasing the diversity of the community. Faecalibacterium, 
Lachnospiraceae, Bacteroides and Alistipes are names of several 
genera that were reduced by ciprofloxacin. The magnitude of 
this effect varied to some degree between individuals. However, 
by 4 weeks after the end of treatment, the makeup of the com-
munity closely resembled its pretreatment state in all three indi-
viduals with the exception of several taxa which failed to recov-
er even 6 months later. During the four week recovery period, 
the participants reported normal intestinal function. The rapid 
resurgence of the pretreatment community indicates strong 
bacterial community resilience. However, the fact that several 
bacterial species did not recover tells that even a short course 
of antibiotics may cause minor permanent changes to gut com-
munity flora. Though the participants did not experience any 
immediate obvious stomach problems from the medication, this 
cannot predict the possibility of long term impacts such as in-
creased susceptibility to allergies or skin irritations (Modi S et al 
2014). Relman found that a second exposure to ciprofloxacin a 
half year after the first treatment causes similar effects but was 
accompanied by incomplete recovery (Dethlefsen and Relman 
2010).
Similar studies using clindamycin showed that the gut Bacteroides 
community never returned to its original composition even two 
years after antibiotic treatment (Jernberg et al 2010). Clearly 
antibiotics impact the bacterial gut population with possible ef-
fects on host wellness.
Which diseases result from antibiotic use?
Campylobacteriosis (stomach ulcer) has been linked with in-
take of antibiotics up to one year before the onset of disease 
(Folkhälsomyndigheten 2014). Candida glabrata, an opportunis-
tic pathogen of the urogenital tract and bloodstream in immu-
nocompromised persons, has been associated with taking of 
specific antibiotics (Ben-Ami 2012). In one large study, fluoro-
quinolones were found responsible for over 55% of cases of 
Clostridium difficile-associated diarrhea, an often fatal disease 
(Pepin et al 2005). Studies have demonstrated using mouse 
models that the two antibiotic-associated pathogens, Salmonella 
typhimurium and Clostridium difficile, infect their host by catab-
olizing mucosal carbohydrates liberated from microbiota by the 
antibiotic streptomycin (Katharine et al 2013). Use of antibiot-
ics in children was significantly associated with Crohn’s disease 
even if 6 months had elapsed between diagnosis and the latest 
intake of antibiotics (Virta et al 2012).  
Aside for the infection of Salmonella typhimurium and 
Clostridium difficile, the exact biological mechanism for most 
of these epidemiological associations is currently unknown. 
However, it is logical to assume that killing off good bacteria 
is causative because we don’t know of any other lasting effects 
of antibiotics, but we did see from the studies  of Modi et al 
(2014)  and Dethlefsen and Relman (2010)  that some of the 
good bacteria decrease and don’t ever reestablish themselves.
Results: Probiotic theory
To counter the adverse effects of antibiotics many have con-
sidered consuming probiotics. The theory behind probiotics is 
that swallowing new live bacteria will replenish the lost bacterial 
communities diminished by the antibiotics. Because a healthy 
gut microbiome is believed to promote and maintain health, 
probiotic yogurt and dietary supplements have been suggested 
even for individuals who have not taken antibiotics. First, though, 
it must be determined that probiotic bacteria are alive and can 
reach the gut when consumed orally.
Do probiotic bacteria die in the acidic pH of the 
stomach before they reach the intestine? 
Critics of probiotics question whether the majority of the bac-
terial communities housed in a probiotic pill survive the acidic 
environment of the stomach on their journey to the intes-
tine. Research has been done to determine the effects of the 
stomach’s acidic environment on probiotic bacteria. It is worth 
noting that Lactobacilli, which are native gut bacteria and are 
included in most probiotic formulations, are acidophilic and are 
not adversely affected by stomach acid (Tannock 2004).  
De Campo et al (2005) performed a double-blind study with 
114 healthy volunteers. After 15 days of yogurt consumption, 
the participants’ feces were analyzed by culture, specific PCR, 
and DNA hybridization for presence of the yogurt organisms 
L. delbrueckii and Streptococcus thermophilus. Detection of 
yogurt lactic acid bacteria in total fecal DNA by bacterial cul-
ture and PCR assay was consistently negative indicating that 
the strong acidic environment of the stomach killed microbes. 
However, Marina Elli et al (2006) showed that the De Campo 
et al’s analytical detection methods were poorly set up. Elli’s 
studies in turn confirmed that yogurt bacteria, especially L. del-
brueckii subsp. bulgaricus, can be retrieved from feces of healthy 
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individuals after a few days of ingestion of commercial yogurt. 
Thus, Marina Elli’s research established that many strains of 
probiotic bacteria do indeed survive transit through the gastro-
intestinal tract. It still is a possibility that though the low pH of 
the stomach does not destroy the entire probiotic population, 
it may limit the number of live bacteria that reach the intestine, 
reducing the effectiveness of the probiotic administration. 
To overcome the possibility that a portion of the probiotic bac-
teria die in the stomach acid, new delivery technology has been 
developed to protect the strains from stomach acid. Scientists 
have constructed a coating for susceptible probiotics to avoid 
this possibility. Bifidobacterium breve, a model probiotic, was 
encapsulated into a multilayer alternating alginate-chitosan 
coating. This construction improved the endurance of B. breve 
during contact with stomach acid. During exposure to in vitro 
gastric conditions, a tremendous increase in viability from that 
seen in free cells was demonstrated (Cook et al 2013). Other 
studies have shown that capsules made of alginate, xanthan gum, 
and carrageenan gum increased the survival of probiotic bac-
teria in acidic stomach conditions (Ding and Shah 2009). Many 
probiotic supplements sold today include protective coatings. 
Though probiotic bacteria in yogurt has no such coating, the 
study of Marina Elli et al (2006) confirms that much of the bac-
teria do survive the acidic stomach environment.
Ancillary support for the survival of probiotic bacteria comes 
from the animal world. Coprophagy is the norm in an over-
whelming number of vertebrae. Rodents, rabbits, pigs, foals and 
gorillas and chimpanzees all eat their feces regularly (Soave and 
Brand 1991). The young of elephants, pandas and hippos eat 
their maternal feces and thereby obtain the bacteria required 
to properly digest and obtain nutrition from vegetation in their 
diet. They are born without these necessary bacteria in their in-
testines (Zilber-Rosenberg 2013). The idea of sharing gut micro-
biota via feces has made its way to human medicine. Fecal bacte-
riotherapy or stool transplants have a well-entrenched place in 
the history of medicine of many ancient cultures. Recent studies 
have shown that C. difficile can be effectively treated with fecal 
transplants (Shultz 2014). The idea behind the consumption of 
feces is very similar to the reason to eat probiotics. It replenish-
es the microbiome with friendly bacteria.
Viability of organisms in capsules
Skeptics have questioned whether probiotic bacteria are alive 
and viable in their capsules or whether they die during pro-
duction or storage. Many studies have been conducted proving 
that the bacteria are indeed alive. This is the general manufac-
turing process of probiotic pills as described by the Lallemand 
Health Solutions probiotic producer (2015): Chosen bacteria 
are inoculated onto a culture media and multiply. Live bacteria 
are then separated from the culture medium by centrifugation; 
they are mixed with a cryoprotectant, to help them survive the 
freeze-drying process. Alternatively, they are vacuum dried or 
spray dried. The dried bacteria form a solid cake which is milled 
into a fine homogeneous powder, each grain of which contains 
approximately 1 billion bacteria. Bacteria powders are blended 
with other carrier and diluent ingredients for the desired bacte-
rial concentrations and then encapsulated and packaged.
Studies into the storage stability of spray-dried (Ananta E et 
al 2005), and freeze dried (Kurtmann L et al 2009) probiotics 
are positive. The bacteria remain alive, although dormant, and 
start to grow again after they reach the moist gut environment. 
Even higher storage stability has been found for vacuum-dried 
probiotic cells. Vacuum-dried cells show much higher stabilities 
than the freeze-dried cells (Foerst P et al 2012). 
Effects of temperature on probiotic quality
Temperature has been shown to play a role in the stability of 
probiotics. Warmth and moisture are the ideal growing condi-
tions for probiotic and gut bacteria. The growth and reactivation 
of these dormant organisms is inhibited in the presence of cold 
air, which holds less moisture and is not in the ideal temperature 
range for these bacteria to thrive. Cold air is therefore optimal 
for storage of probiotics as it keeps the bacteria from activating 
and hence dying before they have a chance to reach the human 
body. High heat can also degrade the viability of these organ-
isms and care should be taken to keep them away from high 
temperatures. A thorough study on the effects of temperature 
on vacuum-dried probiotic bacteria revealed that after three 
months of storage at 4°C cells remained stable with a survival 
rate of 70%. At non-refrigerated temperatures (~37°C) only 
54% of the cells survived (Foerst P et al 2012). Similarly, a study 
of freeze-dried common probiotic lactobacteria strains showed 
that stored at 4°C for three months, the survival rate was 76%, 
while storage at 23°C for the same length of time had only a 37% 
survival rate (Jalali M et al 2012). Similar effects of temperature 
on probiotic bacteria were determined for cells produced by 
spray-drying (Corcoran BM et al 2004). Based on this it would 
be best to store probiotics at refrigerated temperatures. Ideally, 
they should be kept at such temperatures in warehouses, ship-
ment, and stores as well, though this is not currently standard.
It should be noted that as an extra measure, many manufac-
turers add an overage of bacteria to their probiotic products 
to compensate for the expected decline in numbers over time 
(NowFoods).
Probiotics and health
To date there has been insufficient research to prove whether 
probiotics counteract the many adverse effects of antibiotics 
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mentioned above, besides for treating antibiotic-associated diar-
rhea. However, a large number of studies have demonstrated the 
benefits of prophylactic probiotic treatment for general health 
benefits, preventing a variety of ailments, and curing other dis-
eases not associated with antibiotics.
Probiotics as treatment for antibiotic-associated 
diarrhea
In 2012, researchers (Hempel S et al 2012) conducted an ana-
lytical search of hundreds of earlier studies and reviews about 
the effects of probiotics on antibiotic-associated diarrhea. This 
systematic review found that using the lactic acid-producing 
bacteria such as Lactobacillus rhamnosus, or L. casei as well as 
Saccharomyces boulardii [cerevisiae] may be helpful in preventing 
and curing antibiotic-associated diarrhea. The number-needed-to-
treat value (NNT) was found to be 13. This means that statisti-
cally on average out of thirteen susceptible patients being treated 
with probiotics for antibiotic-associated diarrhea, one will bene-
fit. Due to overall poor documentation of the probiotic strains, 
it was not clear if the efficacy of treatment was strain specific. 
Furthermore, the studies were spread over a vast population so 
more research needs to be performed to determine whether 
the elderly, middle-aged, or children would benefit most from 
adjunct probiotics therapy. Another question that requires clarity 
is which specific antibiotics are more likely to cause diarrhea and 
which probiotic strains best combat those particular antibiotics. 
However, the studies analyzed included patients taking a variety of 
antibiotics or did not specify the antibiotics used, limiting any con-
clusive correlation (Hempel S). Because the overall results from 
these studies are promising, many medical experts see no reason 
not to suggest probiotics when prescribing antibiotics (Kligler and 
Cohrssen 2008). 
A more recent (2013) large study targeting 2,941 inpatients over 
65 years of age exposed to broad-spectrum antibiotics found no 
supporting evidence that multi-strain lactobacilli or bifidobacteria 
probiotics were effective in prevention of antibiotic associated 
diarrhea in that group (Allen S et al 2013). 
Studies on the effects of probiotics on the particularly dangerous 
condition, Clostridium difficile colitis, often caused by an impaired 
microbiome due to antibiotics, provide insufficient evidence to 
recommend probiotic therapy even merely as an adjunct treat-
ment (Pillai A and Nelson R 2008). 
Probiotics may shorten the duration of infectious 
diarrhea
Infectious diarrhea is often caused by shigella, E. coli, salmonella, 
and clostridium bacteria.  A meta-analysis of almost 2000 patients 
from 23 studies of infectious diarrhea in both adults and children 
indicates that the duration of symptoms may be shortened by 
the use of probiotics by a mean of 30 hours (Allen SJ et al 2004). 
The majority of the probiotics tested in these studies were lactic 
acid bacteria; two studies used Saccharomyces boulardii. Though 
infectious diarrhea is not necessarily a result of antibiotic treat-
ment, infectious diarrhea from Salmonella often is associated with 
antibiotic use. Thus, in this way probiotics may be considered to 
be counteracting the effects of antibiotics.
Bifidobacterium infantis 35624 reduced 
symptoms of irritable bowel syndrome (IBS)
In a review analyzing 16 randomized clinical trials of irritable 
bowel syndrome (IBS) patients who received either placebo 
or probiotic supplements, Bifidobacterium infantis 35624 was 
effective in reducing irritable bowel syndrome symptoms, such 
as intestinal gas, abdominal pain, bloating, and bowel function 
(Brenner DM et al 2009). There was no evidence of adverse 
results. No other probiotic, including isolated Lactobacillus spe-
cies, showed significant improvement in IBS symptoms in appro-
priately designed randomized clinical trials. 
Another systematic review of the literature revealed that pro-
biotics succeeded in reducing irritable bowel syndrome symp-
toms with a number needed to treat (NNT) of 4 (Moayyedi 
P et al 2010). Almost all probiotic combinations contained 
Bifidobacteria species (Verna 2010). 
Probiotics for constipation
Dr. Mary Morgan, an immunologist and researcher for probi-
otics companies, conducted a meta-analysis to uncover which 
probiotics have the best results for constipation. She found 
the following five are best: Bifidobacterium lactis DN-173 010, 
VSL#3 formula (a probiotic mix), Bifidobacterium lactis Bb-
12, Lactobacillus casei Shirota, and Bifidobacterium longum 
(Morgan 2013).
Probiotics may prevent hepatic encephalopathy 
development from cirrhosis
A recent study shows that probiotics are effective in prevent-
ing the progression of liver cirrhosis to hepatic encephalopathy 
(Lunia MK et al 2013). Cirrhosis is an advanced liver disease 
characterized by replacement of healthy liver tissue with scar 
tissue, leading to progressive loss of liver function. It is usually 
caused by alcoholism, Hepatitis A or Hepatitis B. As cirrhosis is 
irreversible, treatment of cirrhosis focuses on preventing pro-
gression. In a progressed state, cirrhosis may lead to hepatic 
encephalopathy, in which an over accumulation of toxic ammo-
nia in the blood due to loss of liver function brings the patient 
to an altered level of consciousness or coma. Natural members 
of gut flora such as Eubacterium aerofa-ciens, E. lentum, and 
Peptostreptococcus productus produce urease, which hydrolyz-
es urea into ammonia (Suzuki K et al 1979). In a healthy body, 
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this ammonia is absorbed from the intestine into the blood-
stream then filtered out by a functioning healthy liver. Hepatic 
encephalopathy, the result of poor liver function, is commonly 
treated with the sugar, lactulose, which reduces the absorption 
of ammonia from the gut into the bloodstream. The usefulness 
of lactulose is limited by side effects such as diarrhea, bloating, 
and flatulence. The Lunia MK, et al study found that intake of 
a specific set of probiotics will alter the intestinal microbiota, 
preventing development of hepatic encephalopathy in patients 
with cirrhosis. By recolonizing the gut with non-urease produc-
ing bacteria such as those in the supplements used in this study, 
a buildup of ammonia is avoided, thus preventing hepatic coma.
The 86 patients in the treatment group received a regimen of 
probiotics which contained Bifidobacterium breve, B. longum, 
B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, and Streptococcus thermophilus, 110 billion col-
ony-forming units in all, in one capsule 3 times per day. The 
control group included 74 patients. Patients were told to re-
frain from eating any commercial probiotic yogurt. The patients 
were followed up on each month for six months to ascertain 
that they were keeping to their probiotic treatment plan and 
to track the development of any hepatic encephalopathy symp-
toms. The researchers observed that the incidence of hepatic 
encephalopathy was significantly lower in patients treated with 
probiotics. No adverse effects were detected from the probiot-
ics. These results offer a more comfortable and better-tolerated 
alternative to current lactulose treatments (Lunia MK).
A recent study shows that probiotics are effective in prevent-
ing the progression of liver cirrhosis to hepatic encephalopathy 
(Lunia MK et al 2013). Cirrhosis is an advanced liver disease char-
acterized by replacement of healthy liver tissue with scar tissue, 
leading to progressive loss of liver function. It is usually caused by 
alcoholism, Hepatitis A or Hepatitis B. As cirrhosis is irreversible, 
treatment of cirrhosis focuses on preventing progression. In a 
progressed state, cirrhosis may lead to hepatic encephalopathy, 
in which an over accumulation of toxic ammonia in the blood 
due to loss of liver function brings the patient to an altered level 
of consciousness or coma. Natural members of gut flora such 
as Eubacterium aerofa-ciens, E. lentum, and Peptostreptococcus 
productus produce urease, which hydrolyzes urea into ammonia 
(Suzuki K et al 1979). In a healthy body, this ammonia is absorbed 
from the intestine into the bloodstream then filtered out by a 
functioning healthy liver. Hepatic encephalopathy, the result of 
poor liver function, is commonly treated with the sugar, lactu-
lose, which reduces the absorption of ammonia from the gut into 
the bloodstream. The usefulness of lactulose is limited by side 
effects such as diarrhea, bloating, and flatulence. The Lunia MK, 
et al study found that intake of a specific set of probiotics will 
alter the intestinal microbiota, preventing development of hepatic 
encephalopathy in patients with cirrhosis. By recolonizing the gut 
with non-urease producing bacteria such as those in the supple-
ments used in this study, a buildup of ammonia is avoided, thus 
preventing hepatic coma.
The 86 patients in the treatment group received a regimen of 
probiotics which contained Bifidobacterium breve, B. longum, 
B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, and Streptococcus thermophilus, 110 billion col-
ony-forming units in all, in one capsule 3 times per day. The 
control group included 74 patients. Patients were told to re-
frain from eating any commercial probiotic yogurt. The patients 
were followed up on each month for six months to ascertain 
that they were keeping to their probiotic treatment plan and 
to track the development of any hepatic encephalopathy symp-
toms. The researchers observed that the incidence of hepatic 
encephalopathy was significantly lower in patients treated with 
probiotics. No adverse effects were detected from the probiot-
ics. These results offer a more comfortable and better-tolerated 
alternative to current lactulose treatments (Lunia MK).
Probiotics as bowel movement and nutrition 
enhancer in the elderly
Hilla Zaharoni et al (2011) conducted a study to determine 
the preventive impact of probiotics on problems with bowel 
movement and malnutrition in the elderly (Zaharoni H et al 
2011). The study included 215 elderly patients at an orthopedic 
rehabilitation center (107 as control, 108 as probiotic recipi-
ents), age 65 and over. Each participant received a daily dose 
of commercially sold probiotic bacteria. The dosage consisted 
of four strains of Lactobacillus – L. planturum, L. paracasei, L. 
bulgaris, L. acidophilus; three strains of Bifidobacterium – B. 
breve, B.longum, B. infantis; and one strain of Streptococcus, S. 
thermophiles. The control group received a daily placebo packet 
looking exactly like the probiotic complement. After being fed 
daily probiotics or placebo pills for 45 consecutive days in a 
randomized, double-blind, placebo-controlled trial, the patients 
were monitored for 45 follow-up days. The incidences of diar-
rhea were significantly lower among the study group (HR=0.42, 
p=0.04) with a more significant difference among participants 
age 80 and older (HR=0.32, p=0.026). The necessity to use lax-
atives, an indicator of constipation, also showed significant de-
crease in the probiotic group compared with the control group 
(HR=0.74, p=0.032). 
Additionally, healthier levels of transthyretin, reflecting a pos-
itive nutritional intake status, and increased serum albumin 
levels, necessary for proper distribution of body fluids, were de-
tected in the octogenarians of the treatment group compared 
with the control group (P=0.047, p=0.07, p=0.03 respectively) 
but not in the younger age group (between 65 and 80 years 
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of age). This study strongly indicates that the studied bacterial 
strains in commercial probiotics have a positive effect on the 
bowel movements of elderly patients in orthopedic rehabilita-
tion (Zaharoni H et al 2011).
Bifidobacterium lactis (BB-12), Lactobacillus 
reuteri prevents occurrence of infantile fever 
and diarrhea, though not respiratory illness
An important study led by Weitzman Z et al (2005) shows ex-
cellent results for probiotics’ prophylactic effect against fever 
and diarrhea in infants. A placebo-controlled, double-blind 
trial was conducted at 14 child care centers on healthy in-
fants four to ten months old. Infants were assigned randomly 
to either no probiotics or baby formula supplemented with 
Bifidobacterium lactis (BB-12) and Lactobacillus reuteri 55730 
for a period of 12 weeks.  The infants were not breastfed prior 
to the study, and were fed only the assigned formula. The par-
ents agreed not to administer any other probiotic or prebi-
otic supplements. The number of episodes of fever (>100.5 
degrees F), diarrhea, and respiratory illness and the days of 
duration were measured for both groups.
Of 201 participating infants who were similar in gestational 
age, birth weight, and prior breastfeeding, 60 infants were con-
trols, 73 were fed B. lactis, and 68 were fed L. reuteri. Febrile 
outbreaks and diarrheal episodes were nearly double in the 
control group compared to the recipients of B. lactis. The du-
ration of diarrhea was also protracted in the control group. 
Results from the 68 infants of the L. reuteri group were even 
more encouraging. Compared with the controls and even B. 
lactis infants, the L. reuteri group had a substantial decrease 
in number of days with fever, doctor visits, nursery absences, 
and antibiotic medication prescriptions. The probiotic sup-
plements showed no effect on the incidents of respiratory 
illnesses between the groups. 
Bifidobacteria infantis, Streptococcus 
thermophilus, and Bifidobacteria bifidus for 
necrotizing enterocolitis
Prophylactic use of the probiotics, Bifidobacteria infantis, 
Streptococcus thermophilus, and Bifidobacteria bifidus, were 
tested by Alona Bin-Nun et al (2005) to determine their ef-
fect on the incidence and severity of necrotizing enterocoli-
tis. Necrotizing Eterocolitis is a postnatal medical condition 
where portions of the bowel undergo necrosis. Primarily seen 
in premature infants, it is among the most common causes of 
mortality in premature infants. Neonates were randomized to 
either receive a daily feeding supplementation with a probiotic 
mix of 109 colony-forming units per day or to receive no pro-
biotic supplements.
For 72 study and 73 control infants, respectively, birth weight, 
gestational age, and time to reach full feeds were nearly equal. 
The incidence of necrotizing enterocolitis was reduced in the 
study group (4% vs 16.4%). Additionally, necrotizing enterocoli-
tis was less severe in the probiotic-supplemented infants. Three 
of 15 babies who developed necrotizing enterocolitis died, all 
three from the control group. 
Discussion and future study
Over the past two decades there has been significant advance-
ment in the field of probiotics since it has been first suggested in 
1907 by Elie Metchnikoff. These studies have used random undi-
rected criteria for choosing which bacteria from amongst thou-
sands of species and strains to test for potential health benefits. 
They often chose strains occurring in various fermenting foods. 
Each trial has been like a shot in the dark hoping to find a cure. 
The author suggests that future studies focus on the strains 
unique to the gut of residents of the rural village in Burkina 
Faso in the De Filippo et al (2010) study and of other remote 
non-westernized locales for their potential probiotic qualities. 
Epidemiological evidence tells that the improved sanitation, 
sterile industrial foods, and antibiotics of westernized civiliza-
tion has controlled infectious diseases but also has increased the 
incidence of allergic, autoimmune disorders, and inflammatory 
bowel disease (IBD). By selecting gut bacteria unique to isolated 
populations living with an environment and diet of the pre-mod-
ern era, we may discover probiotic beneficial bacteria which can 
restore and implant the health benefits of those primeval and 
rustic lifestyles into the modern urbane world. The De Filippo 
et al study identified bacteria from the genus Prevotella and 
Xylanibacter (Bacteroidetes) and Treponema (Spirochaetes) ex-
clusive to the Burkina Faso population. These results should be 
verified and similar investigations should be made into the gut 
bacteria of other traditional societies such as remote Tibetan 
villages and Northern Okinawa farm towns. New randomized 
clinical trials for probiotic efficacy should be designed utilizing 
the bacterial findings of these remote searches. 
Practical consumer implications; Considerations 
for choosing probiotic supplements
There are hundreds of probiotic supplements available on the 
market. Many of these products have no claim to any support-
ing studies. As probiotics are considered dietary supplements 
and not medications, they do not require certification from 
the Federal Department of Agriculture (FDA). There are great 
variations in the strains of bacteria they contain. It is best to 
buy products that are backed by clinical research. The wise 
consumer will examine the labels of the product to be certain 
that it contains the particular research-backed strains he or she 
desires. If one hopes for a particular cure or health benefit, the 
supplement one chooses should contain strains shown to be 
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Condition Probiotic Bacterial Species Population*
antibiotic-associated diarrhea Lactobacillus rhamnosus, L. casei,   Saccharomyces 
boulardii [cerevisiae]
people younger than 65 years
infectious diarrhea caused by shigella, E. 
coli,  and salmonella
Lactic acid bacteria species, Saccharomyces 
boulardii
adults and children
irritable bowel syndrome (IBS) Bifidobacterium infantis 35624 adults
promoting bowel movements and 
better nutrition intake
Lactobacillus planturum, L. paracasei, L. bulgaris, L. 
acidophilus, Bifidobacterium breve, B.longum, B. 
infantis, Streptococcus  thermophiles
individuals of 65 years and older
fever and diarrhea (prophylactic treat-
ment)
Bifidobacterium lactis (BB-12), Lactobacillus 
reuteri 55730
infants
constipation Bifidobacterium lactis DN-173 010, VSL#3® 
formula (a probiotic mix), Bifidobacterium lactis 
BB-12, Lactobacillus casei Shirota, Bifidobacterium 
longum
adults
necrotizing enterocolitis Bifidobacteria infantis, Streptococcus thermophi-
lus,  Bifidobacteria bifidus
infants
 hepatic encephalopathy 
(prophylactic treatment)
Bifidobacterium breve, B. longum, B. infantis, Lac-
tobacillus acidophilus, L. plantarum, L. paracasei, L. 
bulgaricus, Streptococcus thermophilus
cirrhosis patients
*These particular populations were studied. Effects on other populations are not included unless indicated.
Table 1
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beneficial to that end. Table 1 summarizes researched bacterial 
strains and the conditions they benefit.
Probiotic Yogurt
Many yogurt products claim to be probiotic. Again, these claims 
are not backed by the FDA. Some bacterial strains in yogurt 
have more scientific support than others. According to the 
Dairy Reporter (August 2, 2013), Dannon, Yoplait, Chobani, and 
Stonyfield rank among the most popular brands in the United 
States. Table 2 lists the strains included in commonly available 
yogurts.
Starter bacteria
Most of the brands use Lactobacillus bulgaricus and 
Streptococcus thermophilus as yogurt culture starters to turn 
milk into yogurt.  The only researched health benefits of these two 
species is that they boost the immune system in anorexia patients 
(Nova E et al 2006) and help lactose absorption those who are 
lactose-intolerant (Riskalla SW et al 2000).
Other added strains
Bifidobacterium animalis lactis BB-12 (LaYogurt)
The precise bacteria combination found in La Yogurt hasn’t been 
scientifically researched. However, there have been many trials 
using the strain Bifidobacterium animalis lactis BB-12, which all 
La Yogurt probiotic products contain (*personal communication). 
Studies have shown BB-12 reduces incidences of fever and need 
for antibiotic treatment in infants (Weitzman Z et al 2005). Also, 
it has been demonstrated that negative immune-related effects of 
non-breastfed infants can be significantly reduced by including B. 
animalis lactis BB-12  in their diet (Holscher HD et al 2012).
Bifidobacterium lactis DN-173 010 (Activia®)
On the yogurt ingredient panel this strain is known as Bifidus 
regularis. This strain is well suited to treating intestinal inflamma-
tions such as colitis (Veiga P et al 2010). Studies showed that it 
can reduce symptoms of irritable bowel syndrome (Agrawal A et 
al 2009) and improve digestive comfort and symptom experience 
of adults from the general population (Guyonnet D et al 2009) 
and well as help improve constipation in children (Tabbers MM 
et al 2009).
Lactobacillus casei DN-114 001 (DanActive®)
L. casei DN-114 001, also known as L. casei immunitas, used in 
DanActive®, has great study results. Daily consumption of a prod-
uct containing Lactobacillus casei DN-114 00 has been shown to 
reduce the risk of gastrointestinal and respiratory common infec-
tious diseases in shift workers (Guillemard E et al 2010).
Lactobacillus casei Shirota (Yakult)
The yogurt drink Yakult’s live Lactobacillus casei Shirota has been 
tested for effect on constipation with excellent results. Chronic 
constipation patients experienced a sharp reduction in symptoms 
after only two weeks of drinking Yakult (Koebnick C et al 2003) 
(Cassani E et al 2011).
Yogurt Certification
In the USA,  a ‘Live Active Culture Seal’ (image 1) was introduced 
by the National Yogurt Association to identify refrigerated or fro-
zen yoghurt products which contained at least 108 or 107 viable 
bacteria per gram at the time of manufacture (AboutYogurt.com). 
In heat-treated yogurt, a process done to prolong shelf life or de-
crease yogurt’s natural tartness, these cultures are killed during 
heating after fermentation.
However, because these counts do not differentiate between 
true scientifically proven probiotic strains and mere starter cul-
tures, the National Yoghurt Association’s certification emblem is 
still not reflective of true probiotic value (Senok AC et al 2005). 
One must also check that the strains inside the yogurt are the 
well-researched bacteria discussed above.
Conclusions
While it is true that many strains of bacteria confer positive 
health benefits when taken orally, these bacterial strains demon-
strate great specificity. Precise subspecies and strains have been 
shown to cure certain ailments but not others, to benefit only a 
particular age group, and to provide these advantages only when 
taken on a regular basis. The research in this paper is important 
because it shows the specific ways in which probiotic bacteria 
are effective. The widely spread beliefs about benefits of probi-
otic products are not ensured by any governing body. Research 
indicates that the functions and mechanisms of gut bacteria 
are very complex and therefore there is no reason to assume 
that random “probiotic” bacteria will offer any health benefit. 
In addition, considerations for form and storage of probiotics 
were discussed: namely that alginate coating may aid in probiotic 
colonization and that probiotic supplements should be stored at 
or below 4°C. Consumers should note that the positive results 
in the studies were generally observed after 2-4 weeks or more 
of daily probiotic consumption. Additionally, suggestions for 
future studies utilizing gut bacteria unique to non-modernized 
traditional societies have been made. This paper aids the gener-
al population by providing the necessary knowledge needed in 
order to be an educated consumer of probiotic products.
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